NanoCrystal® Technology offers an effective tool to aid in the screening of new chemical entities (NCE’s) in discovery phase because it can: 

• Formulate with mg - g quantities of NCE
• Rapidly prepare formulations
• Standardize the formulation approach
• Be applicable to all routes of delivery
• Be scaleable through development to commercial manufacturing
• Be used by Biologists, Toxicologists, DMPK and Pharmaceutical Scientists     

Elan’s NanoMill® System can rapidly formulate less than 50 mg of poorly-soluble drug as an aqueous dispersion of NanoCrystal® Particles, suitable for all routes of administration in vivo, or for use in water-soluble screening systems. 

NanoCrystal® Technology offers an effective screening tool for new chemical entities (NCE’s) in the discovery phase of new drug development. 

• In order to assess preclinical activity, an NCE must be administered to animal models.
• NanoCrystal® Technology offers a safe, efficient way to develop a suitable formulation to elucidate initial efficacy and toxicity data in animal models, thus enhancing screening efficacy.
• It is likely that up to 40 percent of NCEs are poorly soluble and most are not progressed to preclinical evaluation because of the formulation challenges presented by their poorly water-soluble solubility.